Skip to main content

Table 5 Percentage change of pharmacodynamic parameters according to SLCO1B1 c.388A > G, SLCO1B1 c.521T > C and SLCO1B3 int7A > G genotypes and SLCO1B1 haplotypes after 12 months of raloxifene treatment in 53 postmenopausal women

From: Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene

Pharmacodynamic parameter Δ FN BMD (%) Δ QUI (%) Δ OC (%)   
genotype SLCO1B1 c.388A > G SLCO1B1 c.521T > C SLCO1B3 int7C > G   
  AA −1.1 (1.5) TT 2.5 (1.1) CC −21.0 (3.5)   
  AG 3.4 (0.6) TC −1.6 (1.4) non CC −33.5 (3.5)   
  GG −0.6 (1.1)       
test/p-value ANOVA 0.001 a t-test 0.033 t-test 0.015   
Pharmacodynamic parameter Δ FN BMD (%) Δ CTX (%) Δ SOS (%) Δ QUI(%)
haplotype *1a *1b *15 *15
  0 copies −0.65 (1.1) 0 copies −20.7 (6.7) 0 copies 0.2 (0.1) 0 copies 2.4 (1.1)
  1 copy 3.5 (0.6) 1 copy −24.7 (5.1) 1 copy −0.3 (0.2) 1 copy −1.9 (1.6)
  2 copies −2.0 (1.6) 2 copies −56.9 (10.4)     
test/p-value test/p-value ANOVA 0.0002 b ANOVA 0.039 c t-test 0.031 t-test 0.03
  1. The values are presented as means (standard errors).
  2. aBonferoni test (ANOVA), p = 0.004 for AA vs. AG, =0.021 for AG vs. GG.
  3. bBonferoni test (ANOVA), p = 0.013 for 0 vs. 1, p = 0.0004 for 1 vs. 2 copies of haplotype*1a.
  4. cBonferoni test (ANOVA), p = 0.035 for 0 vs. 2 copies of haplotype*1b.
  5. Δ FN BMD (%), percentage change of femoral neck bone mineral density; Δ QUI (%), percentage change of quantitative ultrasound index; Δ OC (%), percentage change of osteocalcin; Δ CTX (%), percentage change of serum C-terminal telopeptide fragments of type I collagen; Δ SOS (%), percentage change of heel speed of sound.